These beta glucan studies and information are intended to provide you with a balanced overview relating to your health and well-being. All articles and information are for general education purposes and not to sell specific products. This section does not constitute labeling, endorsements or advertisements for any particular products and should not be interpreted as recommending how to treat any particular diseases or health-related
conditions
Daum T., Rohrbach M.S.; "Zymosan induces selective release of arachidonic acid from rabbit alveolar macrophages via stimulation of a beta-glucan receptor," FEBS Lett 309: 119-122; 1992.
Deimann W, Fahimi HD, "The Appearance of Transition Forms Between Monocytes and Kupffer Cells in the Liver of Rats Treated with Glucan," J Exp Med, p883-897, Apr 1979. * Dept of Anat, U of Heidelberg, Germany.*
Delville, et al., entitled "Le-.beta-1, 3-Glucan et Autres Immunomodulateurs dans L'Unfection lepresis Experimentale Chez La Souris". Acta Leprologica; 77/76: 273-281. 1979.
Deslanders, et al., "Triple-Helical Structure (1,3)-beta-D-Glucans". Macromolecules 13: 1466-1471. 1980.
Diluzio N.R., "Soluble phosphorylated glucan," U.S. Patent 487777, Issued Oct 31, 1989.
Diluzio N.R. (deceased), Williams D.L., Browder I.W.; Soluble phosphorylated glucan: methods and compositions for treatment of neoplastic diseases; U.S. Patent 4818752; 1989.
Diluzio N.R.; Soluble phosphorylated glucan; U.S. Patent 4739046; 1988.
Diluzio N.R. and Williams D.L., " The Roll of Glucan in the Prevention and Modification of Microparasitic Diseases;" in Chemical Regulation of Immunology in Veterinary Medicine, Alan R. Liss, Inc.; pp. 443-456. 1984.
Diluzio N.R.,"Immunopharmacology of glucan: a broad-spectrum enhancer of host defense mechanisms," Trends in Pharmacol. SCI., 4:344-347. 1983. Dept of Physiology, Tulane U, New Orleans, LA. * Quote: (p347) "The broad spectrum of immunopharmacological activities of glucan includes not only the modification of certain bacterial, fungal, viral and parasitic infections, but also inhibition of tumor growth."
Diluzio N.R. Williams D.L. et al, "Comparative evaluation of the tumor inhibitory and antibacterial activity of solubilized and particulate glucan," Recent Results Cancer Res 75:165-172. 1980. * Quote: "Intravenous administration of soluble or particulate glucan resulted in significant reduction in the growth of a syngeneic anaplastic mammary carcinoma and melanoma B16 and enhanced survival."
Diluzio NR, Williams DL; "Enhancement of host susceptibility to Staphylococcus aureus infection by chronic ethanol ingestion-modification by glucan immunostimulation," Alcohol Clin Exp Res 4(3): 254-260. Jul 1980. * Quote: "The administration of glucan significantly prolonged survival of S. Aureus infected control and chronic ethanol mice."
Diluzio NR, Williams DL, et al, "Comparative tumor-inhibitory and anti-bacterial activity of soluble and particulate glucan," Int J Cancer, 24(6): 773-779. Dec 1979. * Quote: "...these studies demonstrate that a soluble glucan preparation exhibits significant anti-tumor and anti-staphylococcal activity."
Diluzio N.R. and Williams D.L., "Glucan-Induced Modification of the Increases Susceptibility of Cyclophosphamide-Treated Mice to Staphylococcus aureus Infection". Cancer Immunol. Immunother.; 6: 73-79. 1979.
Diluzio NR, Williams DL, "Protective effect of glucan against systemic Staphylococcus aureus septicemia in normal and leukemic mice," Infect Immun 20(3): 804-810. Jun 1978. * Dept of Physiology, Tulane U, New Orleans, LA. * Quote: "These data denote that glucan enhances nonspecific resistance to S. aureus sepsis, promotes survival during leukemic episodes, and increases survival time of leukemic mice with experimentally induced staphylococcal infection."
Diluzio N.R., Williams D.L., Cook J.L., Hoffman E.O.; Protective effect of glucan in experimentally induced Candidiasis; J Reticuloendothel Soc 53: 479-490, 1978.
Diluzio N.R., et al., "The Employment of Glucan and Glucan Activated Macrophages in the Enhancement of Host Resistance to Malignancies in Experimental Animals," in The Macrophage in Neoplasia; Academic Press, Inc. New York; pp. 181-198. 1976.
DiLuzio N.R., et al., "Evaluation of the Mechanism of Glucan-Induced Stimulation of the Reticuloendothelial System". J. Reticuloendothelial Soc.; Soc.7: 731-742. 1970.
Di Renzo, L., Yefenof, E., Klein E., "The Function of human NK cells is enhanced by B-Glucan, a ligand of CR3 (CD11b/CD18)". Eur. J. Immunol., 21:1755-1758. 1991.
Doita M, Rasmussen LT, Seljelid R, Lipsky PE, "Effect of soluble aminated beta-1, 3-D-polyglucose on human monocytes: stimulation of cytokine and prostaglandin E2 production but not antigen-presenting function." J Leukoc Biol 49(4): 342-351. Apr 1991. *
Donzis B. A.; Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses; U.S. Patent 5576015; 1996.
Donzis B.A.; Solubilized yeast glucan; U.S. Patent 5519009; 1996.
Donzis B.A.; Photoprotective composition containing yeast extract; U.S. Patent 5397773; 1995.
Donzis B.A.; Method of revitalizing skin by applying topically water insoluble glucan; U.S. Patent 5223491; 1993.
Duan X., Ackerly M. et al; "Evidence for involvement of beta-glucan-binding cell surface lectins."Cell Immunol 157: 393-402; 1994.*
Duvic B., Soderhall K.; "Purification and partial characterization of a beta-1, 3-glucan-binding protein membrane receptor from blood cells of the crayfish Pacifastacus leniusculus," Eur J. Biochem 207: 223-228; 1992.
Enhanced Healing of Decubitus Ulcers by Topical Application of Particulate Glucan. Tulane University School of Medicine; Research Summary. 1984.
Bisu et al, "Studies on the Structure of Polysaccharides (Glucans and Fructans) Produced by Cariogenic Streptococci and on an Enzyme Hydrolyzing the Insoluble Glucan I. Structural Studies of Insoluble Glucan, Soluble Glucan, and Fructans," Chemical Abstracts; vol. 38:pp. 374-381. 1976.
Elstad MR, Parker C et al; "CD11b/CD18 integrin and a beta-glucan receptor act in concert to induce the synthesis of platelet-activating factor by monocytes," J Immunol 152:220-230. 1994. Dept of Med, Veterans Affairs Medical Center, Salt Lake City, UT. *
Engstad RE, Robertsen B, "Recognition of yeast cell wall glucan by Atlantic salmon (Salmo salar L.) macrophages," Dev Comp Immunol 17:319-330. 1993. *
Felippe J., Silva M., Maciel F.M., et al., Infection prevention in patients with severe multiple trauma with the immunomodulator beta (1-3) glucan 1-3 polyglucose (glucan). Surg. Gynecol Obstet., 177: 3833-388. 1993.
Fleet. G. H., et al., "Isolation and Composition of an Alkali-Soluble Glucan from the Cell Walls of Saccharomyces cerevisiae," Chemical Abstracts; 85:89819z. 1976.
Fleet. G. H., et al.,"Isolation and Composition of an Alkali-Soluble Glucan from the Cell Walls of Saccharomyces cerevisiae," Journal of General Microbiology; 94:180-192. 1976.
Franek J, Malina J, Kratka H, "Bacterial infection modulated by glucan: a search for the host defense potentiation mechanisms," Folia Microbiol (Praha) 37(2): 146-152. 1992. *
Giaimis J., Lombard Y., et al; "Both mannose and beta-glucan receptors are involved in phagocytosis of unopsonized, heat-killed Saccharomyces cerevisiae by murine macrophages," J. Leukoc Biol 54: 564-571. 1993. *
Gillet et al., "Particulate beta 1-3 Glucan and Casual Prophylaxis of Mouse Malaria (Plasmodium berghei)". In advances in Exper. Med. and Biology; vol 121A, Escobar and Friedman, eds. Plenum Press, New York, pp. 307-313. 1980.
Glovsky MM, et al; "Effects of particulate beta-1, 3 glucan on human, rat, and guinea pig complement activity," J. Reticuloendothel Soc. 33:401-413. 1983. * Quote: "Glucan administration is associated with the modification of a variety of experimentally induced infectious disease states as well as the inhibition of growth of implantable and spontaneous tumors."
Goldman R., "Characteristics of the B-glucan Receptor of Murine Macrophages". Exp.Cel. Res.; 174:481-490; 1988. *
Goldman R., "Induction of a beta-1, 3-D-Glucan Receptor in P388D1 Cells Treated with Retinoic Acid of 1,25-dihydroxyvitamin D (3)," Immunology; 63:319-324. 1988.
Goto H., Yuasa K., Rylander R.; "(1-->3)-beta-D-glucan in indoor air, its measurement and in vitro activity," Am J. Ind Med 25: 81-83.1994.
Hall MN and Linder P; "The Early Days of Yeast Genetics," Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 1993.
Hara C., et al., "A Branched (1.fwdarw.3)-beta-D-Glucan From a Water Extract of Dictyophora indusiata FISCH," Carb. Res.; 145:237-246. 1986.
Harada, et al., " Agricultural Biological, Growth and beta-Glucan 10C3K Production by a Mutant of Alcaligenes faecalis var. myxogenes in Defined Medium"; vol. 30, No. 8, pp. 764-769. 1966.
Hartland RP, Emerson GW, Sullivan PA, "A secreted beta-glucan-branching enzyme from Candida albicans," Pro R Soc Lond B Biol Sci, 246(1316): 155-160. Biochem Dept, U of Otago, Dunedin, New Zealand. Nov 1991
Hassid, W.Z., Joslyn, M.A., McReady, R.M., "The Molecular Constitution of an Insoluble Polysaccharide From Yeast Saccharomyces Cerevisae"; Journal of American Chemical Society, 1941; 63:295-298. 1941.
Hofemeister, "The beta-glucanase gene from Bacillus amyloliquefaciens shows extensive homology with that of Bacillus subtilis," Gene; 49:177-187. 1986.
Holbrook J.A.C., Parker J.L.; Immunization against Leishmania donovani: glucan as an adjuvant with killed promastigotes; Am J Trop Med Hyg 30: 762-768, 1981.
Holbrook T.W., et al., "Glucan-Enhanced Immunogenicity of Killed Erythrocylic Stages of Plasmodium Benghei"; Infection and Immunity, 32, 542. 1981.
Honda S., et al, "Activation of the alternative pathway of complement by an antitumor (1----3)-beta-D-glucan from Alcaligenes faecalis var. myxogenes IFO 13140, and its lower molecular weight and carboxymethylated derivatives,""Immunopharmacology 11:29-37. 1986. *
Inai et al., "Activation of the Alternative Complement Pathway by Water-Insoluble Glucans of Streptococcus mutans: the Relation between Their Chemical Structures and Activating Potencies." J. Immunol.; 117" 1256-1260. 1976.
Jamas S., Easson D., Ostroff G.R., DavidsonDd; "Method for producing soluble glucans," U.S. Patent 5633369. Issued May 27, 1997. *
Jamas S., Easson D., Ostroff G.R.; "Glucan Preparation," U.S. Patent 5622939. Issued April 22, 1997. *
Jamas S., Easson D., Ostroff G.R.;"Glucan drug delivery system and adjuvant," U.S.Patent 5607677. Issued March 4, 1997. *
Jamas S., Easson D., Ostroff G.R.;"Use of aqueous soluble glucan preparations to stimulate platelet production." U.S. Patent 5532223. Issued July 2, 1996. *
Jamas S., Easson D., Ostroff G.R.;"Use of neutral soluble glucan preparations to stimulate platelet production." U.S. Patent 5488040. Issued January 30, 1996. *
Jamas S., Easson D., Ostroff G.R.;"Method for producing neutral glucans for pharmaceutical applications," U.S. Patent 5322841. Issued June 21, 1994. *<
James S., Chen Y-CJ, Von Der Osten C.H., et al., "Spectral analysis of glucan produced by wild-type and mutant Saccharomyces cerevesiae". Carbohydr. Polym., 13:207-219. 1990.
Janusz M.J., Austen K.F., Czop J.K.; "Isolation of a Yeast Heptaglucoside that Inhibits Monocyte Phagocytosis of Zymosan Particles". The Journal of Immunology; 142:959-965. 1989. Dept of Med, Harvard Med Sch, Boston, MA. * Quote: "Beta-Glucans with 1, 3-and 1, 6 glycosidic linkages are the major structural components of yeast and fungal cell walls and are active pharmacologic agents in host defense systems of plants and animals.... The administration of particulate glucans from S. cerevisiae to laboratory animals induces host resistance to a variety of lethal pathogens by mechanisms involving macrophage stimulation. In vitro studies reveal that bone marrow-derived mouse macrophages and human peripheral blood monocytes possess Beta-glucan receptors that mediate phagocytosis of glucan particles and induce release of proinflammatory mediators..."
Janusz M.J., Austen K.F., Czop J.K.; Phagocytosis of Heat-killed Blastophores of Candida Albicans by Human Monocyte B-glucan Receptors. Immunology; 65:181-185. 1988. *
Janusz M.J., Austen K.F., Czop J.K.; "Lysosomal enzyme release from human monocytes by particulate activators is mediated by beta-glucan inhibitable receptors," J. Immunol 138: 3897-3901. 1987. *
Janusz M.J., et al, "Isolation of Soluble Yeast beta-Glucan that Inhibit Human Monocyte Phagocytosis Mediated by beta-Glucan Receptors," L. Immunol; 137:3270-3276. 1986. *
Jiang B., Sheraton J., et al; "CWH41 encodes a novel endoplasmic reticulum membrane N-glycoprotein involved in beta 1, 6-glucan assembly," J. Bacteriol 178: 1162-1171. 1996.
Jones EW, Broach JR and Pringle JR. ;"The Molecular and Cellular Biology of the Yeast Saccharomyces cerevisiae;" Gene Expression; Cold Springs Harbor Laboratory Press, Cold Spring Harbor, New York. 1992.
Jorgensen J.B., Robertsen B.; "Yeast beta-glucan stimulates respiratory burst activity of Atlantic salmon (Salmo salar L.) macrophages," Dev Comp Immunol 19: 43-57. 1995. *
Jorgensen J.B., "Quantification of high molecular weight (1-3)(1-4)-beta-D-glucan using calcofluor complex formation and flow injection analysis. I. Analytical principle and its standardization," Carlsberg Res. Commun. (1988); 53:277-285. 1988.
|
